News
-
Pieris Pharmaceuticals has announced that it will develop an inhaled anticalin known as PRS-220 for the treatment of idiopathic pulmonary fibrosis and for pulmonary fibrosis following COVID infection, with both programs slated to start in… Read more . . .
-
According to Starpharma, LloydsPharmacy has paused sales of Starpharma’s Viraleze astodrimer sodium antiviral nasal spray after the UK Medicines and Healthcare products Regulatory Agency (MHRA) questioned “promotional claims, including references to SARS-CoV-2 and COVID-19, and the… Read more . . .
-
Aerami Therapeutics said that it has initiated dosing in a Phase 1 clinical trial of its AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH). According to the study description on clinicaltrials.gov, the… Read more . . .
-
Copley Scientific announced that it has joined the Industries Forum of the UK’s Taskforce for Lung Health, and Copley personnel will share their expertise to help advance the taskforce’s five-year plan “to improve the nation’s lung… Read more . . .
-
Generic inhalation device developer Merxin has announced a three-year partnership with the University of Hertfordshire to further research on “the generation of fine mist and particle aerosols from formulations for deep lung delivery.” Merxin will sponsor… Read more . . .
-
Nasus Pharma said that a Phase 1 PK study of its FMXIN002 intranasal dry powder epinephrine demonstrated that FMXIN002 could produce a maximum plasma level comparable to that of epinephrine delivered via EpiPen and reached… Read more . . .
-
SaNOtize Research and Development said that it has gotten approval from Health Canada to move ahead with two Phase 3 trials of its nitric oxide nasal spray for the prevention and treatment of COVID-19. The… Read more . . .
-
Cipla and Glenmark Pharmaceuticals have announced that they have received final approval from the FDA for generic versions of Sunovion’s Brovana arformoterol tartrate inhalation solution for the treatment of COPD. Cipla said that its product… Read more . . .
-
Teva Pharmaceuticals said that it has launched a generic version of Perforomist formoterol fumarate inhalation solution for the treatment of COPD in the US. Perforomist was approved by the FDA in 2007; Teva first submitted… Read more . . .
-
Theravance Biopharma said that a Phase 2 study of its inhaled nezulcitinib (TD-0903) pan-JAK inhibitor in hospitalized COVID-19 patients failed to meet its primary endpoint of respiratory failure free days at Day 28. The study… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.